OncoMatch/Clinical Trials/NCT06442475
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Is NCT06442475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mosunetuzumab for ann arbor stage ii follicular lymphoma.
Treatment: Mosunetuzumab — This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: monoclonal antibody
Exception: peptide-based therapeutic vaccines are allowed
No prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Prior use of any monoclonal antibody within 4 weeks before the first mosunetuzumab administration
Lab requirements
Blood counts
No significant cytopenias defined as platelets < 100,000/uL, hemoglobin < 10 g/dL, or ANC < 1500/uL
Kidney function
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if Gilbert's syndrome); AST ≤ 3 x ULN; ALT ≤ 3 x ULN; GGT ≤ 3 x ULN
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation; Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if Gilbert's syndrome); AST ≤ 3 x ULN; ALT ≤ 3 x ULN; GGT ≤ 3 x ULN; No significant cytopenias defined as platelets < 100,000/uL, hemoglobin < 10 g/dL, or ANC < 1500/uL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify